Navigation Links
Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2013 Sales And EPS Of $675 Million And $1.01, Respectively, Both Record Quarterly Highs. Reaffirms Full Year 2013 Diluted Adjusted EPS Outlook Of $4.10 To $4.20.

ST. LOUIS, April 25, 2013 /PRNewswire/ --

HIGHLIGHTS:Q1 2013 Results (all percentages are to comparable periods in 2012)

  • Q1 2013 reported sales increased 2% to $675 million, a new quarterly high.  Organic sales growth was 1% in the quarter.  Organic sales growth by business unit was (1%) for Research, 3% for Applied and 3% for SAFC Commercial.  Acquisitions completed in 2012 contributed 2% to overall sales growth and changes in foreign currency exchange rates reduced otherwise reportable sales by 1%.  Organic growth was impacted due to approximately two fewer overall shipping days than the same period in the prior year.
  • Q1 2013 reported diluted EPS was $1.01, a new quarterly high, compared to Q1 2012 reported diluted EPS of $0.96 and Q1 2012 adjusted diluted EPS of $0.99.  Excluding a $0.02 negative impact from changes in foreign currency exchange rates, Q1 2013 diluted EPS would have been $1.03.
  • Q1 2013 net cash provided by operating activities and free cash flow were $154 million and $129 million, respectively.  Compared to Q1 2012, free cash flow increased by 15%.
  • On February 12, the Company's Board of Directors approved an increase of 8% in the quarterly cash dividend to $0.215 per share.  This represents the 38th consecutive year of dividend increases.
  • 2013 Outlook (all percentages are to comparable periods in 2012)

  • 2013 guidance is reaffirmed.
  • Full-year organic sales growth is expected to be in the low-to-mid single digit range. 
  • Adjusted diluted EPS (excluding restructuring and other special charges) is expected to be in a range of $4.10 to $4.20.  Full-year effective tax rate is expected to be 28% to 29%. 
  • Net cash provided by operating activities and free cash flow is expected to exceed $560 million and $430 million, respectively.
  • CEO's STATEMENT:Commenting on first quarter 2013 performance, President and CEO Rakesh Sachdev said, "We reported record quarterly sales and diluted EPS of $675 million and $1.01, respectively.  Our overall end markets remain steady with improving pharma trends offset by slower academic spending.  We remain on track to achieve our 2013 full-year organic sales growth and adjusted EPS guidance.

    I am very pleased with the progress we are making in all three of our newly formed market-facing business units – Research, Applied and SAFC Commercial.  Our teams are energized and focused on providing the best science, service and solutions to address customers' needs in these markets. 

    In Research, we continue to see signs that headwinds are abating from the large pharma site consolidations that occurred over the last several years.  We are gaining new business with our solutions-based initiatives such as The Science PlaceSM, a single source marketplace solution to simplify procurement processes and channels.  We also recently signed an agreement with a large biotech customer to manage their medicinal chemistry and biologics portfolio.

    Dealers continue to generate steady organic sales growth, and our Dealers as Partners program has been successfully launched in Europe.  As we anticipated, sales to Academic/Government customers continue to be negatively impacted primarily due to U.S. sequestration-related issues and European funding uncertainties.  We expect the Academic/Government market to remain soft for the remainder of the year, which we have incorporated in our reaffirmed 2013 outlook.

    Within our Applied business unit, our sales to Diagnostics and Testing labs grew strongly in the high single digits. With a rich product portfolio of analytical products, kits and solutions, our sales and marketing teams are developing new accounts and expanding into new geographies. 

    Within SAFC Commercial, we experienced mid-single digit organic sales growth of our Life Science Products and Services.  We remain well positioned to benefit from the therapeutic trend to biologics and high-potency compounds, which was again evidenced by solid growth in our industrial cell culture media business and strong double-digit growth in our custom pharma business.  BioReliance achieved a solid quarter with mid-single digit organic sales growth.  As expected, year-over-year price declines for chemical precursors to the LED industry resulted in lower sales in our Hitech electronics segment.  We are launching new products for the semiconductor and electronic display markets, which are not as price sensitive as the LED market, and are expected to provide growth in the second half of the year.

    We generated strong free cash flow in the quarter and raised our cash dividend for the 38th consecutive year.  We continue to look for growth investments, both organic and inorganic, that fit our strategy of increasing our presence in faster growing Applied and Commercial markets, broadening our Research portfolio to leverage our worldwide sales and distribution channels, increasing our presence in faster growing emerging countries and generating opportunities to significantly increase shareholder value."

    Q1 2013 RESULTS:Reported sales for the first quarter of 2013 were $675 million, a 2% increase from the first quarter of 2012.  Organic sales growth in the quarter was 1%.  Acquisitions completed in 2012 increased sales by 2% and changes in foreign currency exchange rates caused sales to decline by 1%. 

    Research ($361 million in sales, 53% of overall sales)

  • Organic sales declined by 1%.  Changes in foreign currency exchange rates reduced overall Research growth by 2%.
  • Excluding the impact from fewer shipping days, Research sales would have grown organically in the low-single digits.
  • Academic/Government organic sales growth declined in the mid-single digits primarily due to U.S. sequestration-related issues, European funding uncertainty and fewer shipping days.
  • Pharma organic sales growth was flat, which reversed a three-quarter negative trend. 
  • Organic sales growth through our dealer network was in the low-single digits.  Our Dealers as Partners program was launched in the Europe, Middle East, and Africa (EMEA) region and is helping drive strong growth.
  • Applied ($159 million in sales, 24% of overall sales)

  • Organic sales grew by 3%.  Acquisitions contributed 2% to growth and changes in foreign currency exchange rates reduced growth by 1%. 
  • Excluding the impact from fewer shipping days, Applied would have grown organically in the mid-single digits.
  • Diagnostics and Testing organic sales growth was in the high-single digits, driven primarily from sales of critical components for diagnostic kits and sales of standards and certified reference materials to clinical testing laboratories.
  • Sales of products to industrial companies declined in the low-single digits.  A large contributor to the decline was weakness in Asia Pacific (APAC) primarily due to spending reductions from a few large industrial customers.
  • SAFC Commercial ($155 million in sales, 23% of overall sales)

  • Organic sales grew 3%.  Acquisitions contributed 9% to growth and changes in foreign currency exchange rates reduced growth by 1%.
  • Life Science Products and Services organic sales growth was in the mid-single digits, led by strong double-digit growth in contract manufacturing.  The industrial cell culture media business also continued to perform well. SAFC Commercial is expanding capacity at its Irvine, Scotland facility to further address opportunities in this business.  BioReliance grew mid-single digits and continued its sequential improvement that began late last year.
  • Hitech organic sales declined low double-digits.  As expected, a year-over-year pricing decline in metal organic precursors for the LED market was the primary driver of the decline. 
  • Operating income margin in the first quarter of 2013 was 24.6%.  Compared with the prior quarter (fourth quarter of 2012), adjusted operating income margin declined by 60 basis points.  The primary driver for the decline was higher SG&A expense for incentive compensation and increased investments in the realigned business units to better position for future growth.  A reconciliation of reported to adjusted operating income margin is provided on page 11.

    The effective tax rate for the first quarter of 2013 was 26% compared to 32% in the same period last year.  As anticipated, the first quarter of 2013 benefited from the full-year reinstatement of the 2012 US R&D tax credit.

    Free cash flow for the first quarter of 2013 was a strong $129 million, an increase of $17 million from the same period last year.

    Other first quarter 2013 highlights include:

  • Worldwide sales of Research and Applied products through the Company's e-commerce channels grew 2% organically from the same period last year.  Total visits increased by 15% as information content initiatives such as Pubget, a comprehensive online source for scientific publications, drove higher web traffic during the quarter.
  • Organic sales to the Research and Applied markets in APAC grew in the mid-single digits when adjusted for shipping days.  Growth in developed regions was flat while emerging regions grew low double-digits.  China led growth with solid double-digit performance.
  • Organic sales in the EMEA region were flat.  Adjusting for shipping days, both Research and Applied organic sales growth in the region would have been in the mid-single digits.  Academic/Government sales were slightly negative. 
  • Organic sales growth in the Americas was in the low-single digits.
  • The Vetec® value brand was launched in the APAC region to expand the Company's consumables offerings to provide more complete solutions for Research and Applied customers in the region.
  • 2013 OUTLOOK:

  • 2013 outlook remains unchanged.
  • Overall organic sales growth is expected to be in the low-to-mid single digit range.  
  • Adjusted diluted EPS forecast, excluding any restructuring or other special charges, is expected to be in a range of $4.10 to $4.20. 
  • The full-year effective tax rate is expected to be in a range of 28% to 29%.
  • Free cash flow is expected to exceed $430 million. 
  • Net cash provided by operating activities is expected to exceed $560 million.
  • Capital expenditures are expected to be approximately $130 million.
  • OTHER INFORMATION:Cash Flow and Debt:  Net cash provided by operating activities for the first quarter of 2013 was $154 million compared to $144 million for the same period in 2012.  Capital expenditures were $25 million compared to $32 million for the same period last year.  Free cash flow of $129 million in the quarter was used to return $53 million to shareholders through share repurchases and dividends.  The Company's debt to capital ratio was 13% at March 31, 2013 and 24% at March 31, 2012. 

    Share Repurchases:  In the first quarter of 2013, the Company repurchased 0.3 million shares for $27 million.  There were 120 million shares outstanding at March 31, 2013.  The Company expects to continue to offset the dilutive impact of issuing share-based incentive compensation with future repurchases, the timing and amount of which will depend upon market conditions and other factors.

    Cautionary Statement:  This release contains forward-looking statements.  Such statements involve risk and uncertainty, including financial, business environment and projections.  Such statements are preceded by, followed by or that include the words "expected," "expects," "expect," "forecast," "would," "estimate," "will," or similar expressions, and other statements contained herein regarding matters that are not historical facts.  Additionally, this release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs, including, without limitation, statements with respect to the Company's expectations, goals, beliefs, intentions, and the like regarding future sales, earnings, return on equity, cost savings, process improvements, free cash flow, share repurchases, capital expenditures, acquisitions and other matters.  These statements are based on assumptions regarding the Company operations, investments, acquisitions and conditions in the markets the Company serves.  The Company believes these statements are reasonable and well founded.  Such statements in this release are subject to risks and uncertainties, including, among others, certain economic, political and technological factors.  Actual results could differ materially from those stated or implied in this release, due to, but not limited to, such factors as (1) global economic conditions, particularly the uncertainties in the Eurozone and other factors affecting the creditworthiness of our Eurozone customers, (2) changes in pricing and the competitive environment and the global demand for the Company's products, (3) changes in foreign currency exchange rates, (4) changes in research funding and the success of research and development activities, (5) failure of planned sales initiatives in our Research, Applied and SAFC Commercial business units, (6) dependence on uninterrupted manufacturing operations, global supply chain and security of our information systems, (7) changes in the regulatory environment in which the Company operates, (8) changes in worldwide tax rates or tax benefits from domestic and international operations, including the matters described in Note 11 – Income Taxes, to the Company's consolidated financial statements included in Item 8, Part II of the Company's Annual Report on Form 10-K for the year ended December 31, 2012 (the "10-K"), (9) exposure to litigation including product liability claims, (10) the ability to maintain adequate quality standards, (11) reliance on third party package delivery services, (12) an unanticipated increase in interest rates, (13) other changes in the business environment in which the Company operates, (14) acquisitions or divestitures of businesses, and (15) the outcome of the outstanding matters described in Note 12 – Contingent Liabilities and Commitments, to the Company's consolidated financial statements included in Item 8, Part II of the 10-K.  A further discussion of the Company's risk factors can be found in Item 1A of Part I of the 10-K.  The Company does not undertake any obligation to update these forward-looking statements.

    About Sigma-Aldrich:  Sigma-Aldrich is a leading Life Science and High Technology company whose biochemical and organic chemical products, kits and services are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical, diagnostics and high technology manufacturing.  Sigma-Aldrich customers include more than one million scientists and technologists in life science companies, university and government institutions, hospitals and industry.  The Company operates in 37 countries and has approximately 9,000 employees whose objective is to provide excellent service worldwide.  Sigma-Aldrich is committed to accelerating customer success through innovation and leadership in Life Science, High Technology and Service.  For more information about Sigma-Aldrich, please visit the website at

    Non-GAAP Financial Measures:  The Company supplements its disclosures made in accordance with accounting principles generally accepted in the United States (U.S. GAAP) with certain non-GAAP financial measures.  The Company does not, and does not suggest investors should, consider such non-GAAP financial measures in isolation from, or as a substitute for, GAAP financial information.  These non-GAAP measures may not be consistent with the presentation by other companies inside or outside of the Company's industry.  Whenever the Company uses such non-GAAP measures, it provides a reconciliation of such measures to the most closely applicable GAAP measure.  See the Supplemental Financial Information on pages 10 and 11 for these reconciliations.

    With over 60% of sales denominated in currencies other than the U.S. dollar, management uses currency adjusted sales growth when analyzing Company performance, and believes it is useful as well to investors to judge the Company's performance.  Organic sales growth data presented in this release excludes currency and acquisitions impacts.  The Company calculates the impact of changes in foreign currency exchange rates by multiplying current period activity by the difference between current period exchange rates and prior period exchange rates.  The result is the defined impact of "changes in foreign currency exchange rates."  While we are able to report past currency impacts, we are unable to estimate changes that may occur later in 2013 to applicable exchange rates.  Any significant changes in currency exchange rates would likely have a significant impact on reported growth rates due to the volume of sales denominated in foreign currencies.

    Management also uses the following non-GAAP measures to judge its performance and ability to pursue opportunities that enhance shareholder value:  adjusted net income and EPS; adjusted operating income margin (reconciled on page 11); and free cash flow (defined on page 9).  Management believes this non-GAAP information is useful to investors as well.

    Pubget is a registered trademark of Pubget Corporation.


     SIGMA-ALDRICH CORPORATIONConsolidated Statements of Income (Unaudited)(in millions except per share amounts)Three Months EndedMarch 31,20132012Net sales$
    5Cost of products and services sold331310Gross profit344355Selling, general and administrative expenses161160Research and development expenses1718Acquisition transaction costs-5Operating income166172Interest, net11Income before income taxes165171Provision for income taxes4354Net income$
    7Net income per share - Basic$
    .97Net income per share - Diluted$
    .96Weighted average number of shares outstanding - Basic120121Weighted average number of shares outstanding - Diluted121122 


    SIGMA-ALDRICH CORPORATIONConsolidated Balance Sheets (Unaudited)(in millions)(Unaudited)March 31,December 31,20132012ASSETSCurrent assets:Cash and cash equivalents$
    724Accounts receivable, net398356Inventories711722Deferred taxes3032Other 9095Total current assets1,7001,929Property, plant and equipment:Property, plant and equipment2,0012,011Less - accumulated depreciation(1,190)(1,182)Property, plant and equipment, net811829Goodwill, net675691Intangibles, net270282Other12589Total assets$
    3,820LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Notes payable$
    383Accounts payable154160Payroll 5255Income taxes 4526Other7477Total current liabilities414701Long-term debt300300Pension and post-retirement benefits132135Deferred taxes6664Other7274Total liabilities9841,274Stockholders' equity:Common stock202202Capital in excess of par value294276Common stock in treasury(2,294)(2,271)Retained earnings4,3664,270Accumulated other comprehensive income2969Total stockholders' equity2,5972,546Total liabilities and stockholders' equity$

     SIGMA-ALDRICH CORPORATIONConsolidated Statements of Cash Flows (Unaudited)(in millions)Three Months EndedMarch 31,20132012Cash flows from operating activities:Net income$
    7Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization3532Deferred income taxes620Stock-based compensation expense86Other(2)(3)Changes in operating assets and liabilities:Accounts receivable(51)(46)Inventories4(16)Accounts payable(4)6Income taxes2113Other, net1515Net cash provided by operating activities154144Cash flows from investing activities:Capital expenditures(25)(32)Purchases of short-term investments(51)(16)Proceeds from sales of short-term investments2021Acquisitions of businesses, net of cash acquired-(389)Other, net(3)(3)Net cash used in investing activities(59)(419)Cash flows from financing activities:Net issuance of short-term debt(294)193Dividends(26)(24)Share repurchases(27)(25)Proceeds from exercise of stock options1014Excess tax benefits from stock-based payments37Net cash used in financing activities(334)165Effect of exchange rate changes on cash(14)3Net change in cash and cash equivalents(253)(107)Cash and cash equivalents at January 1724665Cash and cash equivalents at March 31$
    558Free cash flow(1)$
    2(1) Net cash provided by operating activities less capital expenditures. 


    SIGMA-ALDRICH CORPORATIONSupplemental Financial Information - (Unaudited)Sales Growth by Business UnitThree Months EndedMarch 31, 2013AcquisitionAdjustedReportedCurrencyBenefit(Organic)Research(3)%(2)%—%(1)%Applied & Industrial4 %(1)%2 %3 %SAFC11 %(1)%9 %3 %Total Customer Sales2 %(1)%2 %1 %Business Unit Sales(in millions)First
    Quarter 2013Second
    Quarter 2013Third
    Quarter 2013Fourth
    Quarter 2013Total
    361Applied & Industrial159———159SAFC155———155Total Customer Sales$
    Quarter 2012Second
    Quarter 2012Third
    Quarter 2012Fourth
    Quarter 2012Total
    ,398Applied & Industrial153151148146598SAFC140165156166627Total Customer Sales$
    2,623Income Statement RatiosThree Months EndedMarch 31,20132012Gross profit51.0 %53.4 %S,G&A expenses23.9 %24.1 %Acquisition transaction costs—%0.7 %Operating income24.6 %25.9 %Net income18.1 %17.6 %Effective tax rate26.1 %31.6 % 


    SIGMA-ALDRICH CORPORATIONSupplemental Financial Information - (Unaudited)Reconciliation of Reported Net Income to Adjusted Net IncomeNet IncomeDiluted Earnings (in millions)Per ShareThree Months EndedThree Months EndedMarch 31,March 31,2013201220132012Reported net income$
    .96Acquisition transaction costs—4—0.03Adjusted net income$
    .99Reconciliation of Reported Operating Income to Adjusted Operating Income(in millions)Three Months EndedMarch 31,20132012Reported operating income$$
    72Acquisition transaction costs—5Adjusted operating income$$
    77Reconciliation of Reported Operating Income Margin to Adjusted Operating Income MarginThree Months EndedMarch 31,December 31,September 30,June 30,2013201220122012Reported Operating Income Margin24.6%25.0%24.4%25.2%Restructuring cost—%0.2%0.6%0.6%Adjusted Operating Income Margin24.6%25.2%25.0%25.8%Reconciliation of Reported Earnings Per Share to Adjusted Earnings Per ShareThree Months EndedMarch 31,20132012Reported Earnings Per Share$
    .96Currency0.02n/a Adjusted Earnings Per Share$
    .96Reconciliation of Free Cash Flow(in millions)Three Months EndedMarch 31,20132012Net cash provided by operating activities$
    44Less: Capital expenditures(25)(32)Free cash flow$

    SOURCE Sigma-Aldrich
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Sigma-Aldrich Announces Q1 2013 Earnings Conference Call
    2. Sigma-Aldrich Corporations Sigma Life Science Business to Distribute Worldwide Olink Biosciences Protein Interaction Analysis Technology
    3. Sigma-Aldrich Reports Record Full Year 2012 Results. Reports Q4 2012 Diluted EPS Of $0.96. Q4 2012 Sales Increased 7%. Full Year 2012 Adjusted Diluted EPS Was $3.85. Expects Full Year 2013 Adjusted Diluted EPS To Increase To $4.10 - $4.20.
    4. Sigma-Aldrich Aligns Into Three New Market-Focused Business Units
    5. Sigma-Aldrich (NASDAQ: SIAL) Declares $0.20 Quarterly Dividend
    6. Sigma-Aldrich Enhances Customer Focus in China - Unveils Dynamic New Website and Expands Product Offering Through Vetec Brand
    7. Sigma-Aldrich Corporation To Present At Upcoming Investor Conferences
    8. Sigma-Aldrich Accelerates Analytical Research and Extends Benefits of Fused-Core Particle Technology to All HPLC Users with the Launch of New Ascentis Express 5 Micron Particle by Supelco
    9. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
    10. Morgan & Morgan Announces Investigation of MAP Pharmaceuticals (NASDAQ: MAPP)
    11. SHAREHOLDER ALERT: Morgan & Morgan announces an investigation of Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and whether senior management and the board of directors violated fiduciary duties owed to Vertex shareholders.
    Post Your Comments:
    (Date:11/26/2015)... -- Research and Markets ( ) has announced ... by Type (Dressings, Therapy Devices, Active Wound Care), Application ... and Geography - Global Forecast to 2020" report ... --> The purpose of this report is ... global advanced wound care market. It involves deep dive ...
    (Date:11/26/2015)... November 26, 2015 ... adds "Global Repaglinide Industry ... Report on China Repaglinide Market, 2010-2019" ... data and information to its online ... . --> ...
    (Date:11/26/2015)... Research and Markets ( ) ... Future Horizons and Growth Strategies in the Italian ... Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report ... --> This new 247-page report ... drug monitoring market, including emerging tests, technologies, instrumentation, ...
    Breaking Medicine Technology:
    (Date:11/29/2015)... Aliso Viejo, CA (PRWEB) , ... November 29, ... ... is an all new and unique analog distortion effect tool designed specially for ... to their footage, and create limiltess looks with the easy-to-use modification controls. Destoying ...
    (Date:11/28/2015)... ... November 28, 2015 , ... Safe storage for contraceptive devices ... inventors, one from Lakewood, New Jersey and the other from Bradley Beach, New Jersey, ... to save the expense of having to replace NuvaRings more often than necessary. As ...
    (Date:11/27/2015)... , ... November 28, 2015 , ... There is only ... outperform our billings from last year? , This question has not been an easy ... coming to the retirement age and the younger workforce don’t share the same discipline ...
    (Date:11/27/2015)... ... , ... The rapid speed at which Americans are aging ... is needed, especially with Alzheimer’s, dementia and other cognitive conditions becoming more prevalent. ... part of this equation: 80 percent of medical care occurs in the home, ...
    (Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... Lizzie’s ... , The company is offering customers 10% off of their purchase of lice treatment ... treatment at full price. According to a company spokesperson. “Finding lice is a sure ...
    Breaking Medicine News(10 mins):